VOLUNTARY ANNOUNCEMENT - TRD205 "AT2R ANTAGONIST" GRANTED THE CDE'S BREAKTHROUGH THERAPY DESIGNATION

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR TQB3454 TABLET “IDH1 INHIBITOR”

VOLUNTARY ANNOUNCEMENT - FURTHER DEEPENING OF THE EXCLUSIVE STRATEGIC COLLABORATION WITH GSK

VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR TQC3721 WITH ASTRAZENECA

VOLUNTARY ANNOUNCEMENT -ACCEPTANCE OF NEW DRUG APPLICATION FOR ROPIVACAINE HYDROCHLORIDE SUSTAINED-RELEASE SOLUTION

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2026

NEXT DAY DISCLOSURE RETURN